Major Shareholder Announcement
September 28 2016 - 2:46PM
COPENHAGEN, Denmark, Sept. 28, 2016 (GLOBE NEWSWIRE)
--
Company Announcement
- Major shareholder announcement for Genmab A/S
Copenhagen, Denmark; September 28, 2016 - Genmab A/S (Nasdaq
Copenhagen:GEN) announces under reference to Section 29 of the
Danish Securities Trading Act that Baillie Gifford & Co has
corrected their previous notification of September 22, 2016.
Baillie Gifford & Co has informed us that the number of voting
rights held on September 22, 2016 was partly calculated on the
basis of shares held but over which Baillie Gifford & Co had no
voting authority. Baillie Gifford & Co have therefore today
corrected their notification from September 22, 2016 to state that
their indirect ownership in Genmab A/S, as of September 22, 2016,
amounted to 1,330,773 shares, which amounted to 2.21% of the share
capital and voting rights in Genmab A/S.
About Genmab Genmab is a publicly traded,
international biotechnology company specializing in the creation
and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two
approved antibodies, Arzerra(r) (ofatumumab) for the treatment of
certain chronic lymphocytic leukemia indications and DARZALEX(r)
(daratumumab) for the treatment of heavily pretreated or double
refractory multiple myeloma. Daratumumab is in clinical development
for additional multiple myeloma indications and for non-Hodgkin's
lymphoma. Genmab also has a broad clinical and pre-clinical product
pipeline. Genmab's technology base consists of validated and
proprietary next generation antibody technologies - the DuoBody(r)
platform for generation of bispecific antibodies, and the
HexaBody(r) platform which creates effector function enhanced
antibodies. The company intends to leverage these
technologies to create opportunities for full or co-ownership of
future products. Genmab has alliances with top tier pharmaceutical
and biotechnology companies. For more information visit
www.genmab.com. Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor
Relations & Communications T: +45 33 44 77 20; M: +45 25
12 62 60; E: r.gravesen@genmab.com This Company Announcement
contains forward looking statements. The words "believe", "expect",
"anticipate", "intend" and "plan" and similar expressions identify
forward looking statements. Actual results or performance may
differ materially from any future results or performance expressed
or implied by such statements. The important factors that could
cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety
issues, uncertainties related to product manufacturing, the lack of
market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion
of these risks, please refer to the risk management sections in
Genmab's most recent financial reports, which are available on
www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement
nor to confirm such statements in relation to actual results,
unless required by law. Genmab A/S and its subsidiaries own the
following trademarks: Genmab(r); the Y-shaped Genmab logo(r);
Genmab in combination with the Y-shaped Genmab logo(tm); the
DuoBody logo(r); the HexaBody logo(tm); HuMax(r); HuMax-CD20(r);
DuoBody(r); HexaBody(r) and UniBody(r). Arzerra(r) is a trademark
of Novartis AG or its affiliates. DARZALEX(r) is a trademark of
Janssen Biotech, Inc.
Company Announcement no. 46 CVR no. 2102 3884
Genmab A/S Bredgade 34E 1260 Copenhagen K
Denmark
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024